“…W e read with great interest the article by Coleman et al 1 concerning the major role of thrombin activatable fibrinolysis inhibitor (TAFI) in fibrinolytic shutdown (SD) after injury. In this observational cohort study, the authors found that Group 2 (fibrinolysis SD, n = 35) had significantly higher plasmin-antiplasmin (median, 4.7 [interquartile range (IQR), 1.7-9.3] vs. 1.4 [1.0-2.1] μg/mL in Group 1; p = 0.002) and higher TAFI (median, 152.5% [IQR,.7%] vs. 121.9% [IQR, 93.2-155.6%] in Group 1, p = 0.04) compared with Group 1 (normal fibrinolysis, n = 21).…”